Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are starting to get content posted on Findit. Seen this with other companies like AIKI and GWHP. Helps with traffic to the corporate website and brings the company more online eye balls learning about what the company is about. Been seeing more companies using Findit lately. So RSTN use them back in June and July I think when it was UBID and the site traffic went up and so did volume.
https://www.findit.com/lobe-sciences-pinksheet-gtsif
Bid above the offer pre market.
MMID Bid Size Time (ET)
GTSM 0.85 1,000 8:35:10 AM
MMID Ask Size Time (ET)
CSTI 0.81 1,000 8:30:13 AM
It's on the move pre-market. Amy predictions? 1.6200 +0.14 (8.11%)
Before hours: 8:52
Latest short report on GTSIF https://www.otcshortreport.com/company/GTSIF
Quite a bit over past 30 days. Have a look.
Feb 02 NA NA NA 577,056 109,840 19.03
Feb 01 NA NA NA 1,167,460 492,744 42.21
Jan 29 NA NA NA 1,215,485 450,733 37.08
Jan 28 NA NA NA 4,286,885 1,599,457 37.31
Jan 27 NA NA NA 2,570,877 833,844 32.43
Jan 26 NA NA NA 1,087,853 236,060 21.70
Jan 25 NA NA NA 952,153 574,398 60.33
Jan 22 NA NA NA 1,110,643 950,676 85.60
Jan 21 NA NA NA 450,092 169,334 37.62
Jan 20 NA NA NA 569,426 411,786 72.32
Jan 19 NA NA NA 435,373 178,869 41.08
Jan 15 NA NA NA 350,399 114,130 32.57
Jan 14 NA NA NA 866,109 535,322 61.81
Jan 13 NA NA NA 313,813 202,993 64.69
Jan 12 NA NA NA 449,774 257,941 57.35
Jan 11 NA NA NA 674,198 243,780 36.16
Jan 08 NA NA NA 502,120 256,172 51.02
Jan 07 NA NA NA 345,667 121,293 35.09
Jan 06 NA NA NA 608,142 372,443 61.24
Jan 05 NA NA NA 384,389 149,698 38.94
Jan 04 NA NA NA 851,122 486,178 57.12
LOBE SCIENCES LTD. — GTSIF With the recent dip coming off of big volume days only 2 months ago, with some news this one could be poised to make a move.
Dec 14, 2020 0.1450 0.1845 0.1331 0.1660 0.1660 11,687,101
Dec 11, 2020 0.1450 0.1450 0.1162 0.1205 0.1205 6,417,829
Dec 10, 2020 0.0900 0.1465 0.0809 0.1450 0.1450 19,609,741
Lobe Sciences Ltd. has launched a preclinical research study using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”).
The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami's Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.
https://www.lobesciences.com/technology
News out today: AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board
New Board Member Brings Expertise in Oncology Research
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- [url]AIkido Pharma Inc (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Neil H. Bander, M.D., a physician-researcher at Weill Cornell Medicine, has joined the Company's Scientific Advisory Board.
"Dr. Bander heads one of the world's most experienced and accomplished teams in antibody-targeted therapy of prostate cancer at Cornell University and is a widely respected inventor of patented technologies and recognized expert in the field of urological oncology," commented Mr. Anthony Hayes, CEO of AIkido. "Importantly, Dr. Bander is the inventor of targeted radiopharmaceutical therapy technology at Convergent Therapeutics, Inc. which we are proud to support. We are honored to have him join our team of advisors and work more directly in our efforts to advance the development of this technology."
"Using his clinical background and laboratory efforts, Dr. Bander has exemplified the role of surgeon-scientist," added Mr. Hayes. "His research has spawned novel clinical trials that are unique in urological oncology and have already made a difference in the lives of prostate cancer patients. We look forward to leveraging his expertise as we continue to develop our platforms and forge a path towards the treatment of cancer."
Dr. Bander, M.D. completed fellowship training in both tumor immunology and urological oncology at Memorial Sloan-Kettering Cancer Center in New York City. Subsequently, at New York-Presbyterian Hospital-Weill Cornell Medical Center (NYPH/WCM), where he is the Bernard and Josephine Chaus Professor of Urologic Oncology, he has focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy. As a result of his efforts, his research group developed the first antibodies to prostate-specific membrane antigen (PSMA) that could effectively bind prostate cancer cells. As a result of his efforts, PSMA is now recognized as the most prostate-cancer specific cell surface antigen known and is the target of a wide variety of anti-cancer technologies. The NYPH/WCM Uro-Oncology research team has sponsored more than 15 clinical trials with anti-PSMA antibodies and more recently, small molecule PSMA agents, in prostate cancer patients with more than 500 patients treated in these trials.
Dr. Bander said, "I look forward to joining my Weill-Cornell colleague, Dr. Scott Tagawa, on AIkido's SAB, as well as the other AIkido team members, to generate advances that make an impactful difference in the lives of cancer patients."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
Cision
Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-adds-inventor-dr-neil-h-bander-md-to-scientific-advisory-board-301220019.html
SOURCE AIkido Pharma Inc.
Originally published Tue, February 2, 2021, 8:00 AM
AIkido Pharma Setting Up to Be Major Player in
The Booming $176BIL Anti-Cancer Therapeutics Sector
With Their Latest Blockbuster News!
Dear Fellow Trader,
Immediately turn your attention to AIkido Pharma Inc. (AIKI)
AIkido Pharma Is An Artificial Intelligence-Cancer Fighting-Biotech
Company Like You’ve Never Seen Before.
The Company has several bullish catalysts in the pipeline, and is on the verge of disrupting a $176BIL Anti-Cancer Therapeutics Market, with latest Blockbuster News AIKI secures early investment in Next Generation Radiotherapy Company Convergent Therapeutics currently in Human Phase 2 Trials for Treatment of Prostate Cancer.
This acquisition, instantly positions AIkido Pharma as a significant player in rapidly expanding $176 Billion Anti-Cancer Therapeutics Market!
Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.
Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy ("PRRT") that targets the prostate-specific membrane antigen ("PSMA") present on prostate cancer cells.
The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.
The key component of Convergent's PRRT prostate cancer therapy is its proprietary drug, CONV 01-a, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter.
The function of CONV 01-a is unique in that it not only binds specifically to the PSMA receptor on prostate cancer cells, but also stimulates the internalization of the receptor along with itself and its powerful radioactive payload directly into tumor cells.
Convergent is presently conducting two sets of human clinical trials using CONV 01-a as a single agent treatment for prostate cancer.
The first is a Phase 1a/2a Single Ascending Dose Trial of CONV 01-a and the results are expected to be released in Q2 2021.
In August of 2020, Convergent began a second Phase 1b/2a trial to test the efficacy of multiple ascending doses of CONV 01-a.
If FDA approved, CONV 01-a would be the first antibody drug approved to direct a radioisotope into prostate cancer cells, and the first drug approved for the use of 225Ac in cancer treatment.
Another company is currently studying PSMA I&T-ß, containing 177Lu, and has just completed a phase 3 trial in prostate cancer. Separately, Novartis (NYSE: NVS) is pursuing FDA approval for another 177Lu-small molecule drug for prostate cancer treatment, designated 177Lu-PSMA-617, which also binds PSMA. Novartis has recently completed a phase 3 registration trial for treatment of metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer. Like PSMA I&T-ß, Novartis's 177Lu-PSMA-617 may also be a promising candidate for use with CONV 01-a in the proprietary dual PRRT therapy.
Aikido's CEO, stated, "This is by far the most advanced technology in which the Company has participated. The first of the human trials is wrapping up, with data to be reported shortly, and with the remaining trials either underway or scheduled to begin imminently. Participation in this advanced work represents a major and potentially transformative step for the Company and we are honored to be a part of it. I optimistically anticipate the first of the results to be released next quarter. We will update our shareholders as soon as the data is released."
AIkido Pharma Setting Up To Be A Major Player In The $176 Billion
Anti-Cancer Therapeutics Market That Is Exploding Exponentially!
Another Catalyst Is Convergent Therapeutics Experienced
First in Class Operational Team.
The operational team are some of the brightest people in the world!
Once you wrap your head around who the operational team and founder is, I can assure you that you too will see we could potentially have another big breakout gainer on our hands.
Philip Kantoff, MD CEO - Convergent Therapeutics
Memorial Sloan Kettering Cancer Center (MSK)
Chairman, Department of Medicine, 2015-present
Grew faculty at MSK’s Department of Medicine by >200 (currently ~484 total) through recruitment of national and international clinical and research leaders in oncology
Increased the annual research funding of the Department of Medicine to over $300 million dollars. An increase of 78% since starting in 2015
Created and pushed forward research programs that have produced dozens of cancer related FDA drug approvals
Steered the department through the COVID-19 crisis
Neil Bander, MD CSO / Founder - Convergent Therapeutics
Weill Cornell Medicine
Bernard and Josephine Chaus Professor of Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine
His team has the world’s largest experience in antibody discovery and clinical development in urological oncology.
Developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients.
Pioneered the clinical validation of PSMA and PSMA-Targeted Therapeutics (Radionuclides and Antibody-Drug Conjugates).
John Cullity, MD MBA CFO / CBO
Managing Director at BioSynergy Partners, a life science advisory spun out of Torreya New York where he was CBO.
Provides strategic advisory on M&A, partnering and financing to life-science companies worldwide.
Chairman Race Oncology (RAC.ASX). Director of several life sciences start-ups.
Oncology BD team leader and Head of Strategic Pricing at Sanofi, Health Economist at Schering Plough, Consultant at A.T. Kearney.
Board certified internist: Royal College of Physicians, UK. Wharton MBA.
Upgraded Bullish - FDCT is Off to A Strong Start!
Are You Watching? Looking Very Strong as Volume Surges!
So far, FDCT is breaking out to the upside fast hitting a high of $.57 yesterday up 23% from previous sessions close.
There has been a massive shift into Bitcoin and Cryptocurrency, prices have climbed after stock trading app Robinhood stepped in to restrict users from GameStop and other stocks that have surged in recent days.
We are in the midst of another Crypto Frenzy and companies like FDCT have the potential to make serious moves this week.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have FDCT pulled up on your trading screen.
Sincerely,
Editor In Chief, OTCtipReporter Team
This guy nailed it. Findit, Inc (OTCMKTS: FDIT) Video Chart for 6/16/20
BlueHorseshoeStocks
Have you checked out Convergent Therapeutics, Inc? It's a startup pharmaceutical company that is focused on developing next generation radiopharmaceutical therapy for prostate cancer and other applications. Its proprietary technology involves peptide receptor radionuclide therapy (“PRRT”) developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine. With them teaming up with AIKI this is something to look at.
Profit Alert: AIKI Rockets From Alert of $.84 to Staggering $2.15 TODAY
Running Up +155.95% (More Huge Profits) What Did I Tell YOU...
Profit Alert: GWHP Rockets From Alert of $.49 to Staggering $2.12 TODAY
Running Up +332.65% (More Huge Profits) What Did I Tell YOU...
Profit Alert: SPONF Rockets From Alert of $.009 to Staggering $.0318 TODAY
Running Up +253.33% (More Huge Profits) What Did I Tell YOU...
Another Incredible Day for My Alerts...
What did I tell you?
Congrats, SPONF rocketed to a staggering high of $.0318 today running up +253.33% from my alert price on Jan 19th of $.009/share.
Also, one of my previous picks AIKI which I alerted you on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.75, providing members with +108.33% gains from my premarket alert at $.84/share. today it Rocketed to a high of $2.15 up +155.95% from alert price.
I alerted you my #1 Covid-19 Diagnostics stock GWHP on Jan 12th at $.49/share, today it Rocketed to a high of $2.12 providing members with +332.65% gains.
I told you I was going to be sending you a lot of explosive picks this month that have the potential to move big and to move FAST!
For anyone that may have missed my email from earlier, I've included a copy of my alert below:
Breaking News Hits Wire! SILO Announces Reaches Terms with
University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Dear Fellow Trader,
Immediately turn your attention to Silo Pharma Inc. (SILO)
SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
News Link Here - snapshot below
JANUARY 26, 2021
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.
Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."
-----------------------------------------------------------------------------------------------------
This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.
As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.
...Now take a look at the Short Report on SILO:
Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.
These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…
You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.
Regards,
Your PPF Team
Profit Alert: SPONF Rockets From Alert of $.009 to Staggering $.0318 TODAY
Running Up +253.33% (More Huge Profits) What Did I Tell YOU...
Another Incredible Day for My Alerts...
What did I tell you?
Congrats, SPONF rocketed to a staggering high of $.0318 today running up +253.33% from my alert price on Jan 19th of $.009/share.
I alerted you my #1 Covid-19 Diagnostics stock GWHP on Jan 12th at $.49/share, today it Rocketed to a high of $2.12 providing members with +332.65% gains.
Also, one of my previous picks AIKI which I alerted you on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1..94, providing members with +108.33% gains from my premarket alert at $.84/share... Today it Rocketed to a premarket high of $1.66 up +97.61% from alert price.
I told you I was going to be sending you a lot of explosive picks this month that have the potential to move big and to move FAST!
For anyone that may have missed my email from earlier, I've included a copy of my alert below:
Breaking News Hits Wire! SILO Announces Reaches Terms with
University of Maryland Baltimore for Exclusive License of Central Nervous
Homing Peptide for Neuroinflammatory Disease
Dear Fellow Trader,
Immediately turn your attention to Silo Pharma Inc. (SILO)
SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
News Link Here - snapshot below
JANUARY 26, 2021
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.
Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."
If you haven't yet read SILO full profile, do so HERE
Click here to get the full Report!
This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.
As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.
...Now take a look at the Short Report on SILO:
Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.
These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…
You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.
Sincerely,
Editor In Chief, OTCtipReporter Team
Profit Alert: SPONF Rockets From Alert of $.009 to Staggering $.0318 TODAY
Running Up +253.33% (More Huge Profits) What Did I Tell YOU...
Another Incredible Day for My Alerts...
What did I tell you?
Congrats, SPONF rocketed to a staggering high of $.0318 today running up +253.33% from my alert price on Jan 19th of $.009/share.
I alerted you my #1 Covid-19 Diagnostics stock GWHP on Jan 12th at $.49/share, today it Rocketed to a high of $2.12 providing members with +332.65% gains.
Also, one of my previous picks AIKI which I alerted you on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.94, providing members with +108.33% gains from my premarket alert at $.84/share... Today it Rocketed to a premarket high of $1.66 up +97.61% from alert price.
I told you I was going to be sending you a lot of explosive picks this month that have the potential to move big and to move FAST!
For anyone that may have missed my email from earlier, I've included a copy of my alert below:
Breaking News Hits Wire! SILO Announces Reaches Terms with
University of Maryland Baltimore for Exclusive License of Central Nervous
Homing Peptide for Neuroinflammatory Disease
Dear Fellow Trader,
Immediately turn your attention to Silo Pharma Inc. (SILO)
SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
News Link Here - snapshot below
JANUARY 26, 2021
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.
Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."
If you haven't yet read SILO full profile, do so HERE
Click here to get the full Report!
This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.
As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.
...Now take a look at the Short Report on SILO:
Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.
These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…
You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.
Sincerely,
Editor In Chief, OTCtipReporter Team
Breaking News Hits Wire! SILO Announces Reaches Terms with
University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Dear Fellow Trader,
Immediately turn your attention to Silo Pharma Inc. (SILO)
SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
News Link Here - snapshot below
JANUARY 26, 2021
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.
Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."
If you haven't yet read SILO full profile, do so HERE
Click here to get the full Report!
This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.
As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.
...Now take a look at the Short Report on SILO:
Image
Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.
These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…
You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.
If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.
Sincerely,
Editor In Chief, OTCtipReporter Team
[url]
https://www.otctipreporter.com/[/url][tag]insert-text-here[/tag]
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
Silo Pharma, Inc.
Tue, January 26, 2021, 8:18 AM·2 min read
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
https://finance.yahoo.com/news/silo-pharma-reaches-terms-university-131800548.html
The covered GWHP FDIT AND AIKI as well. COMPANY: Silo Pharma Inc.
SYMBOL: SILO
ALERT RANGE: $.35 - $.37
Dear Fellow Trader,
First things first, I’d like to extend a “Huge Welcome” to all of our New Members and for our loyal ones, a big Congrats on our recent big picks!
We are coming off recent gainers like my previous pick Aikido Pharma (AIKI) which ran up +108.33%. I alerted AIKI on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.75, providing members with +108.33% gains from my premarket alert at $.84/share.
Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.
Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.
If you liked your previous picks above that I just mentioned, I believe you are going to love your NEXT New Breakout Stock for Monday... SILO
Turn Your Complete Attention to SILO
Monday's Focus Stock
Immediately turn your attention to Silo Pharma Inc. (SILO)
?Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research based out of New Jersey. Not many people know this but New Jersey is the Global Leader when it comes to Pharmaceutical and Biotechnology Industries.
Keep Reading to See Why You Need to Pull Up
Silo Pharma Inc. (SILO) Right Now
Many Psychedelic Stocks Just Experienced Triple-digit
Returns - as much as +799%, +471%, and +302%
Silo Pharma Inc. (SILO) Could be Getting Ready to Take Off
Silo Pharma Inc. states their mission is to identify assets to license and fund the research which they believe will be transformative to the well-being of patients and the healthcare industry.
In these uncertain times, the mental health of the nation and beyond is being put to the test. More than ever, creative new therapies and lines of thought are needed to address health challenges of today. Combining their resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.
If we look at the chart pattern on any of the leading psychedelic stocks, we should see a nice series of higher highs and higher lows. The reason for this increased interest in Psychedelics is improved mental health.
More than 264M people worldwide suffer from depression and mental health disorders are on the rise in every country in the world. Mental health is something every one of us should be talking about. Since serotonin and norepinephrine reuptake inhibitors came to market in the 1980s and 1990s, we have not seen a lot of life changing new pharmacological therapies for mood disorders until the FDA approved esketamine in March 2019.
Silo’s goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.
Silo Pharma Inc’s management and founders have played key
roles in numerous successful biotech companies.
Silo Pharma Inc. (SILO) is well-capitalized with access to additional funds as oppor·tunities present themselves.
Silo Pharma Inc’s CEO and Founder, Eric Weisblum, has over 25 years of Wall street experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.
POTENTIAL CATALYST THAT COULD SEND SHARES
OF SILO PHARMA (SILO) SOARING NEXT WEEK
Potential Catalyst #1: Silo Pharma Receives $1 Million in Up Front Patent Licensing Deal for its Psilocybin Cancer Therapeutic Applications: The license agreement (the “Agreement”) with Aikido Pharma Inc. (Nasdaq: AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop Therapeutics for the treatment and complications of Cancer. (This Could be Huge)
Potential Catalyst #2: Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights. Many Psychedelic Stocks Just Experienced Triple-digit Returns- as much as +799%, +471%, and +302%
Potential Catalyst #3: One of the Strongest and Talented Management Teams that I have seen in the Psychedelic Space. SILO has direct ties to Johns Hopkins which is one of the leading Universities in the Psychedelic Space. (This Could be Huge)
Potential Catalyst #4: Silo Pharma announced Blockbuster News they're to explore unique peptide delivery of psilocybin utilizing this novel technology represents key differentiator in emerging psilocybin space. Silo Pharma announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology.
Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.
This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS).
These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.
Potential Catalyst #5: Silo Pharma Launches Scientific Advisory Board with Appointment of a Physician of John Hopkins University: “Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”
Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics.
Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Bottom line, SILO could turn out to be another potential double-digit breakout gainer like my previous win·ners.
So, without wasting any more time, don't delay and pull up SILO on your trading screen for Monday before you miss out on another huge potential win·ner, with tremendous upside potential.
...And if you remember, I recently Alerted on Aikido Pharma (AIKI) at $.84 and rocketed to an intraday high of $1.75 -- Showing Off Potential Gains of +108.33% within a 24-Hour period.
Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.
Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.
Could Silo Pharma Inc. (SILO) be my next Massive Win·ner?
Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights.
Let’s Take a Closer Look At Silo Pharma Inc. (SILO) and why I think they are Ready for a Potential Massive Breakout to the Upside.
Silo Pharma Inc. (SILO) Growth Plans:
- Identify and target assets to license
- Partner with world-class medical research organizations
- Research and study indications
- Target FDA designations: Break Through Therapy, Orphan & Fast Track
- Big pharma partnerships
Silo Pharma Inc. (SILO) Psychedelics Opportunity:
- Build out industry leading scientific advisory board
- Combine generics with Psilocybin, MDMA, LSD
- Build Intellectual Property through research and innovation
- Targeting Mental health and rare neurological diseases
Last week, even The UFC Announced it was “Diving into” Psychedelics
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
The promotion has been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues, UFC president Dana White told MMA Junkie on Wednesday.
"We're diving into that," Dana White said.
UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports" last month. Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins over the past few weeks.
The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1 million last week. Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research.
"Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental-health problems. We want to be on board and we want to be first."
Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research.
Currently, psilocybin and other psychedelics are classified by the U.S. government as illegal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses.
However, views on psychedelics are changing. Oregon lega·lized psilocybin in a vote last year.
"Our research has demonstrated therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression," states the Johns Hopkins Center for Psychedelic & Consciousness Research website.
Former UFC flyweight contender Ian McCall has been working with psilocybin and athletes and has taken part in a study with Johns Hopkins, he told ESPN's Michael Rothstein last year. McCall said he has already had discussions with the UFC.
"When you go into a cage, when you go into a ring and you fight and even football, you're giving and receiving [post-traumatic stress syndrome] and no one wants to talk about it, but that's what's happening," McCall said. "Your trauma is stored in your tissue, so you're actually giving and receiving PTSD while you're in there and that's a big reason why I work in psychedelics, to try and fix those exact things. We need to take care of these athletes a little better, just like we need to do with vets."
Novitzky said he has spoken to athletes who have experimented with psychedelics such as ayahuasca, and those who have struggled with addiction or mental health have said the drug has been extremely helpful. The UFC exec said he's not sure on a timeframe on when the promotion could do something in the psychedelic field, but that the desire is there.
"We want to do it the right way," Novitzky said. "We want to get all the government approvals if we're going to do something. We want to figure out how we're going to recruit fighters. Unfortunately, it's not something that happens overnight. But Dana has basically instructed me: 'Hey I want this looked into. Bring me some potential avenues we can be involved.'"
White said, like with the UFC's participation in the brain health study, there is a desire to look more into potential therapies for fighters with brain issues. UFC veteran Spencer Fisher opened up about his health problems, including lesions on his brain, in an interview with MMAFighting.com that was published Tuesday.
"He's not the first and he's definitely not gonna be the last," White said of Fisher. "This is a contact sport. Anyone has ever done this [when they were] younger -- myself included -- is dealing with brain issues. It's part of the gig."
SILO PHARMA RECENT NEWS :
JANUARY 19, 2021
Silo Pharma to Participate in Virtual Conference
on Investing in Psychedelics
NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.
JANUARY 13, 2021
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System
Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore relating to a study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis.
According to the National Multiple Sclerosis Society, an estimated 1 million people live with MS in the United States. Silo Pharma is seeking to develop treatments, including the use of targeted drug delivery to the Central Nervous System (CNS) as a means of overcoming many of the limitations of current therapies. The study will seek to identify the various cell types that are responsive to a series of peptides to understand how drug-carrying liposomes ultimately interact with the CNS tissue cells.
“We are to be collaborating with researchers at the University to begin a study of this novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. This study is an important step in gathering research and data to treat rare neurologic diseases with the CNS peptide,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “We believe that, when combined with the findings of our previously announced investigator-sponsored study, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson's disease and to understand its mechanism of action, we will gain valuable data needed to analyze the potential of these peptides to be used in combination with psilocybin, LSD, or traditional drugs, as potential therapeutic agents.”
JANUARY 11, 2021
Silo Pharma Provides Details of Patent License Agreement
for Psilocybin and Cancer Applications
Silo Pharma to Receive Upfront Payment Combination of Cash and Preferred Stock Totaling $1MIL
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.
In consideration for granting the license, Silo Pharma received a one-time cash payment of $500K and shares of newly designated Convertible Preferred Stock valued at $500K on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.
“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity. Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”
Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.
JANUARY 6, 2021
Silo Pharma Inc. Receives $1M Dollars in UpFront Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma’s patent application relates to using a novel peptide with Psilocybin as a therapeutic.
Eric Weisblum, CEO of Silo Pharma, Inc, stated “We are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs that can lead to improved care. This agreement is structured to provide $500K in an upfront cash payment as well as equity currently valued at $500K from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.”
Now Let’s Take a Closer Look The Ama·zing Management Team Behind Silo Pharma Inc. (SILO)
Eric Weisblum - CEO
Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both inlicensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum is involved in his community and can often be found on the soccer field with his family of four. He holds a B.A. from the University of Hartford’s Barney School of Business.
Kevin Muñoz - Board Member
Dr. Kevin Muñoz, 43, was appointed to the Board of Directors on October 1, 2020. Dr. Muñoz currently serves as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes. Kevin began his career with Harlem Health Promotion Center in New York City as a Research Assistant where he was responsible for data collection and interpretation. Dr. Muñoz earned a Bachelor of Science from the University of Michigan where he graduated with distinction and a Doctor of Medicine from Xavier University School of Medicine, Aruba NA.
Wayne Linsley - Board Member
Wayne D. Linsley, 64, has served as a director of the Company since January 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skill set including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting. He has a bachelor’s in business administration from Siena College in Loudonville, NY.
Since 2009 he has worked for and is currently a Vice President for CFO Oncall, Inc., a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10K, 10Q, 8K, etc.) Edgar, etc. He often negotiates on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc.
Matthew W. Johnson, Ph.D. - Scientific Advisor
Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert on psychedelics, other drugs, and addiction. Working with psychedelics since 2004, he has published over 50 scientific papers on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon medical approval. He has guided over 100 psychedelic sessions. Matt also conducts behavioral economic research on both addiction and sexual risk. He conducts research with most psychoactive drug classes, was 2018 President of the Psychopharmacology Division of the American Psychological Association, and is the 2020-2021 President of the International Society for Research on Psychedelics. Interviewed by: 60 Minutes (CBS News), New York Times, Washington Post, Wall Street Journal, BBC, CNN, Fox Business News, NPR, and Michael Pollan.
Dr. Jos Woolley MD/PhD - Scientific Advisor
Dr. Josh Woolley MD/PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (SFVAMC). He received both his MD and his PhD in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand why people with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders, have trouble with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.
Dr. Peter Hendricks, Ph.D. - Scientific Advisor
Dr. Peter Hendricks, Professor in the Department of Health Behavior, University of Alabama at Birmingham is currently researching the use of psilocybin to see if it will help individuals addicted to cocaine stop using the harmful drug. He theorizes that psilocybin, which is the active compound found in Psilocybe mushrooms, also known as "magic mushrooms," can be understood as working from multiple angles, including neurobiological and psychological, with an emphasis on subjective transcendent experiences of awe. Hendricks is able to talk about his research as well as novel and more effective treatments for substance abuse dependence, with specific areas of focus on tobacco, cocaine and polysubstance abuse in vulnerable populations.
As you can see, there are multiple bullish catalysts signaling breakout gain potential!
It’s important to remember that historically, small-cap biotech, biopharmaceutical,
life sciences, nutraceutical and therapeutics companies have been my biggest gainers that are cut from the same cloth as SILO!
I am urging all of our members to add SILO to the top of their watch list right now, and be ready Monday morning at the opening bell!
Sincerely,
Editor In Chief, OTCtipReporter Team
They recently covered AIKI FDIT AND GWHP COMPANY: Silo Pharma Inc.
SYMBOL: SILO
ALERT RANGE: $.35 - $.37
Dear Fellow Trader,
First things first, I’d like to extend a “Huge Welcome” to all of our New Members and for our loyal ones, a big Congrats on our recent big picks!
We are coming off recent gainers like my previous pick Aikido Pharma (AIKI) which ran up +108.33%. I alerted AIKI on Jan 6th and it started trading premarket at approx. $.84 and rocketed to an intraday high of $1.75, providing members with +108.33% gains from my premarket alert at $.84/share.
Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.
Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.
If you liked your previous picks above that I just mentioned, I believe you are going to love your NEXT New Breakout Stock for Monday... SILO
Turn Your Complete Attention to SILO
Monday's Focus Stock
Immediately turn your attention to Silo Pharma Inc. (SILO)
?Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research based out of New Jersey. Not many people know this but New Jersey is the Global Leader when it comes to Pharmaceutical and Biotechnology Industries.
Keep Reading to See Why You Need to Pull Up
Silo Pharma Inc. (SILO) Right Now
Many Psychedelic Stocks Just Experienced Triple-digit
Returns - as much as +799%, +471%, and +302%
Silo Pharma Inc. (SILO) Could be Getting Ready to Take Off
Silo Pharma Inc. states their mission is to identify assets to license and fund the research which they believe will be transformative to the well-being of patients and the healthcare industry.
In these uncertain times, the mental health of the nation and beyond is being put to the test. More than ever, creative new therapies and lines of thought are needed to address health challenges of today. Combining their resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.
If we look at the chart pattern on any of the leading psychedelic stocks, we should see a nice series of higher highs and higher lows. The reason for this increased interest in Psychedelics is improved mental health.
More than 264M people worldwide suffer from depression and mental health disorders are on the rise in every country in the world. Mental health is something every one of us should be talking about. Since serotonin and norepinephrine reuptake inhibitors came to market in the 1980s and 1990s, we have not seen a lot of life changing new pharmacological therapies for mood disorders until the FDA approved esketamine in March 2019.
Silo’s goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.
Silo Pharma Inc’s management and founders have played key
roles in numerous successful biotech companies.
Silo Pharma Inc. (SILO) is well-capitalized with access to additional funds as oppor·tunities present themselves.
Silo Pharma Inc’s CEO and Founder, Eric Weisblum, has over 25 years of Wall street experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.
POTENTIAL CATALYST THAT COULD SEND SHARES
OF SILO PHARMA (SILO) SOARING NEXT WEEK
Potential Catalyst #1: Silo Pharma Receives $1 Million in Up Front Patent Licensing Deal for its Psilocybin Cancer Therapeutic Applications: The license agreement (the “Agreement”) with Aikido Pharma Inc. (Nasdaq: AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop Therapeutics for the treatment and complications of Cancer. (This Could be Huge)
Potential Catalyst #2: Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights. Many Psychedelic Stocks Just Experienced Triple-digit Returns- as much as +799%, +471%, and +302%
Potential Catalyst #3: One of the Strongest and Talented Management Teams that I have seen in the Psychedelic Space. SILO has direct ties to Johns Hopkins which is one of the leading Universities in the Psychedelic Space. (This Could be Huge)
Potential Catalyst #4: Silo Pharma announced Blockbuster News they're to explore unique peptide delivery of psilocybin utilizing this novel technology represents key differentiator in emerging psilocybin space. Silo Pharma announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology.
Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.
This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS).
These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.
Potential Catalyst #5: Silo Pharma Launches Scientific Advisory Board with Appointment of a Physician of John Hopkins University: “Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”
Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics.
Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Bottom line, SILO could turn out to be another potential double-digit breakout gainer like my previous win·ners.
So, without wasting any more time, don't delay and pull up SILO on your trading screen for Monday before you miss out on another huge potential win·ner, with tremendous upside potential.
...And if you remember, I recently Alerted on Aikido Pharma (AIKI) at $.84 and rocketed to an intraday high of $1.75 -- Showing Off Potential Gains of +108.33% within a 24-Hour period.
Earlier last week, I alerted you my Covid-19 Diagnostics stock Global WholeHealth Partners (GWHP) at $.49 and rocketed to a high of $2.17 Showing Off Potential Gains of +342.85%.
Then I Alerted you on Cannabis Suisse Corp. (CSUI) and it broke out to the upside fast hitting a high today of $.149/share up +62.30% from Thursday’s intraday low of $.0918.
Could Silo Pharma Inc. (SILO) be my next Massive Win·ner?
Investor Interest In This Space is Sending Psychedelic Stocks Soaring To Incredible New Heights.
Let’s Take a Closer Look At Silo Pharma Inc. (SILO) and why I think they are Ready for a Potential Massive Breakout to the Upside.
Silo Pharma Inc. (SILO) Growth Plans:
- Identify and target assets to license
- Partner with world-class medical research organizations
- Research and study indications
- Target FDA designations: Break Through Therapy, Orphan & Fast Track
- Big pharma partnerships
Silo Pharma Inc. (SILO) Psychedelics Opportunity:
- Build out industry leading scientific advisory board
- Combine generics with Psilocybin, MDMA, LSD
- Build Intellectual Property through research and innovation
- Targeting Mental health and rare neurological diseases
Last week, even The UFC Announced it was “Diving into” Psychedelics
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
The promotion has been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues, UFC president Dana White told MMA Junkie on Wednesday.
"We're diving into that," Dana White said.
UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports" last month. Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins over the past few weeks.
The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1 million last week. Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research.
"Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental-health problems. We want to be on board and we want to be first."
Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research.
Currently, psilocybin and other psychedelics are classified by the U.S. government as illegal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses.
However, views on psychedelics are changing. Oregon lega·lized psilocybin in a vote last year.
"Our research has demonstrated therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression," states the Johns Hopkins Center for Psychedelic & Consciousness Research website.
Former UFC flyweight contender Ian McCall has been working with psilocybin and athletes and has taken part in a study with Johns Hopkins, he told ESPN's Michael Rothstein last year. McCall said he has already had discussions with the UFC.
"When you go into a cage, when you go into a ring and you fight and even football, you're giving and receiving [post-traumatic stress syndrome] and no one wants to talk about it, but that's what's happening," McCall said. "Your trauma is stored in your tissue, so you're actually giving and receiving PTSD while you're in there and that's a big reason why I work in psychedelics, to try and fix those exact things. We need to take care of these athletes a little better, just like we need to do with vets."
Novitzky said he has spoken to athletes who have experimented with psychedelics such as ayahuasca, and those who have struggled with addiction or mental health have said the drug has been extremely helpful. The UFC exec said he's not sure on a timeframe on when the promotion could do something in the psychedelic field, but that the desire is there.
"We want to do it the right way," Novitzky said. "We want to get all the government approvals if we're going to do something. We want to figure out how we're going to recruit fighters. Unfortunately, it's not something that happens overnight. But Dana has basically instructed me: 'Hey I want this looked into. Bring me some potential avenues we can be involved.'"
White said, like with the UFC's participation in the brain health study, there is a desire to look more into potential therapies for fighters with brain issues. UFC veteran Spencer Fisher opened up about his health problems, including lesions on his brain, in an interview with MMAFighting.com that was published Tuesday.
"He's not the first and he's definitely not gonna be the last," White said of Fisher. "This is a contact sport. Anyone has ever done this [when they were] younger -- myself included -- is dealing with brain issues. It's part of the gig."
SILO PHARMA RECENT NEWS :
JANUARY 19, 2021
Silo Pharma to Participate in Virtual Conference
on Investing in Psychedelics
NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that Founder and CEO Eric Weisblum will participate in the “Investing in Psychedelics Series: Building Value Through IP” virtual conference hosted by The Canadian Securities Exchange (CSE), CFN Media Group (OTCQB: CNFN) and Zuber Lawler on Wednesday, January 20, 2021. The live panel discussion is scheduled to begin at 1 PM EST. and will be followed by a Q&A session.
JANUARY 13, 2021
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous System
Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore relating to a study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis.
According to the National Multiple Sclerosis Society, an estimated 1 million people live with MS in the United States. Silo Pharma is seeking to develop treatments, including the use of targeted drug delivery to the Central Nervous System (CNS) as a means of overcoming many of the limitations of current therapies. The study will seek to identify the various cell types that are responsive to a series of peptides to understand how drug-carrying liposomes ultimately interact with the CNS tissue cells.
“We are to be collaborating with researchers at the University to begin a study of this novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. This study is an important step in gathering research and data to treat rare neurologic diseases with the CNS peptide,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “We believe that, when combined with the findings of our previously announced investigator-sponsored study, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson's disease and to understand its mechanism of action, we will gain valuable data needed to analyze the potential of these peptides to be used in combination with psilocybin, LSD, or traditional drugs, as potential therapeutic agents.”
JANUARY 11, 2021
Silo Pharma Provides Details of Patent License Agreement
for Psilocybin and Cancer Applications
Silo Pharma to Receive Upfront Payment Combination of Cash and Preferred Stock Totaling $1MIL
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million. The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.
In consideration for granting the license, Silo Pharma received a one-time cash payment of $500K and shares of newly designated Convertible Preferred Stock valued at $500K on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.
“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity. Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”
Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.
JANUARY 6, 2021
Silo Pharma Inc. Receives $1M Dollars in UpFront Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma’s patent application relates to using a novel peptide with Psilocybin as a therapeutic.
Eric Weisblum, CEO of Silo Pharma, Inc, stated “We are excited about this opportunity as we continue to execute our plan to bring novel therapeutics to patients inflicted with neurological disorders and rare diseases, which we hope will bring about breakthroughs that can lead to improved care. This agreement is structured to provide $500K in an upfront cash payment as well as equity currently valued at $500K from a NASDAQ listed company. The Agreement also provides for Silo to collect royalties should the technology be commercialized.”
Now Let’s Take a Closer Look The Ama·zing Management Team Behind Silo Pharma Inc. (SILO)
Eric Weisblum - CEO
Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both inlicensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum is involved in his community and can often be found on the soccer field with his family of four. He holds a B.A. from the University of Hartford’s Barney School of Business.
Kevin Muñoz - Board Member
Dr. Kevin Muñoz, 43, was appointed to the Board of Directors on October 1, 2020. Dr. Muñoz currently serves as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes. Kevin began his career with Harlem Health Promotion Center in New York City as a Research Assistant where he was responsible for data collection and interpretation. Dr. Muñoz earned a Bachelor of Science from the University of Michigan where he graduated with distinction and a Doctor of Medicine from Xavier University School of Medicine, Aruba NA.
Wayne Linsley - Board Member
Wayne D. Linsley, 64, has served as a director of the Company since January 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skill set including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting. He has a bachelor’s in business administration from Siena College in Loudonville, NY.
Since 2009 he has worked for and is currently a Vice President for CFO Oncall, Inc., a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10K, 10Q, 8K, etc.) Edgar, etc. He often negotiates on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc.
Matthew W. Johnson, Ph.D. - Scientific Advisor
Matthew W. Johnson, Ph.D., Professor at Johns Hopkins, is an expert on psychedelics, other drugs, and addiction. Working with psychedelics since 2004, he has published over 50 scientific papers on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon medical approval. He has guided over 100 psychedelic sessions. Matt also conducts behavioral economic research on both addiction and sexual risk. He conducts research with most psychoactive drug classes, was 2018 President of the Psychopharmacology Division of the American Psychological Association, and is the 2020-2021 President of the International Society for Research on Psychedelics. Interviewed by: 60 Minutes (CBS News), New York Times, Washington Post, Wall Street Journal, BBC, CNN, Fox Business News, NPR, and Michael Pollan.
Dr. Jos Woolley MD/PhD - Scientific Advisor
Dr. Josh Woolley MD/PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (SFVAMC). He received both his MD and his PhD in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand why people with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders, have trouble with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.
Dr. Peter Hendricks, Ph.D. - Scientific Advisor
Dr. Peter Hendricks, Professor in the Department of Health Behavior, University of Alabama at Birmingham is currently researching the use of psilocybin to see if it will help individuals addicted to cocaine stop using the harmful drug. He theorizes that psilocybin, which is the active compound found in Psilocybe mushrooms, also known as "magic mushrooms," can be understood as working from multiple angles, including neurobiological and psychological, with an emphasis on subjective transcendent experiences of awe. Hendricks is able to talk about his research as well as novel and more effective treatments for substance abuse dependence, with specific areas of focus on tobacco, cocaine and polysubstance abuse in vulnerable populations.
As you can see, there are multiple bullish catalysts signaling breakout gain potential!
It’s important to remember that historically, small-cap biotech, biopharmaceutical,
life sciences, nutraceutical and therapeutics companies have been my biggest gainers that are cut from the same cloth as SILO!
I am urging all of our members to add SILO to the top of their watch list right now, and be ready Monday morning at the opening bell!
Sincerely,
Editor In Chief, OTCtipReporter Team
Have a look at this recent newsletter. Ready for your next potential triple digit gainer?
Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research.
I recommend you take a moment and click here and discover how you can get this stock’s name & ticker symbol.
http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=538224&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8
If I told you that psychedelic stocks were among some of the best stocks to buy for the next decade, you’d probably look at me funny. I wouldn’t blame you. But, believe it or not, psychedelic stocks are some of the best stocks to buy for the next 10 years. Here is where you need to go now to get the name of this secret stock before everyone else.
This specific secret company is making incredible strides in this sector. It is focused on bringing targeted medicine to market, through novel delivery systems, psychedelic assisted psychotherapy, and Active Pharmaceutical Ingredient grade psilocybin manufacturing. To that effect, while it is still early in the medicinal psychedelic space, hefty valuations are being placed on the most serious contenders competing for a slice of the $100 billion pie.
This Secret Company with a market capitalization of less than $30 million CAD, provides investors with an opportunity which could prove highly lucrative as the industry develops and matures! Just make sure you own a piece of it before it is too late.
Click Here to review a thorough report detailing the above on this "Secret Company" and discover for yourself why you need to invest in it right away!
http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=538224&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8
Sincerely,
Editor In Chief, OTCtipReporter Team
Have a look at this recent newsletter. Ready for your next potential triple digit gainer?
Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research.
I recommend you take a moment and click here and discover how you can get this stock’s name & ticker symbol.
insert-text-here
If I told you that psychedelic stocks were among some of the best stocks to buy for the next decade, you’d probably look at me funny. I wouldn’t blame you. But, believe it or not, psychedelic stocks are some of the best stocks to buy for the next 10 years. Here is where you need to go now to get the name of this secret stock before everyone else.
This specific secret company is making incredible strides in this sector. It is focused on bringing targeted medicine to market, through novel delivery systems, psychedelic assisted psychotherapy, and Active Pharmaceutical Ingredient grade psilocybin manufacturing. To that effect, while it is still early in the medicinal psychedelic space, hefty valuations are being placed on the most serious contenders competing for a slice of the $100 billion pie.
This Secret Company with a market capitalization of less than $30 million CAD, provides investors with an opportunity which could prove highly lucrative as the industry develops and matures! Just make sure you own a piece of it before it is too late.
Click Here to review a thorough report detailing the above on this "Secret Company" and discover for yourself why you need to invest in it right away!
insert-text-here
Sincerely,
Editor In Chief, OTCtipReporter Team
Do you have link to Epic Stock website? Would like to get alerts on GWHP from them. Thanks
More News out this morning
Global WholeHealth Partners Corp (GWHP-OTC) to Announce that Global is Now Selling Access Bio Antigen Test
San Clemente 1/21/2021 11:30:00 AM GMT
Charles Strongo, CEO of Global WholeHealth Partners Corp (GWHP-OTC), comments on https://www.cbsnews.com/news/covid-death-toll-united-states-expected-500k-february/ regarding the potential of 500,000 deaths by mid-February, as stated by the incoming director of the Centers for Disease Control. Mr. Strongo states that “the statement about the death toll reaching 500,000 is staggering, and it is our responsibility to be tested and to follow the rules of the CDC. We must keep testing, wearing masks and following the rules of social distancing, as directed by the CDC. We can defeat this virus. We must not take it lightly. It has killed thousands.”
Mr. Strongo states, “Antibody and Antigen Testing is critical to fight against CoViD 19 SARS 2.”
https://www.findit.com/gwhp-corp/news/1813099/global-wholehealth-partners-corp-gwhp-otc-to-announce-that-global-is-now
Who is Epic? Do you have anything you can post from them showing the coverage?
Following OTC TIP REPORTER and their coverage. With GWHP making an amazing gain this past day, they tend to cover FDIT each month. So far no coverage. If it does come this month with OTC Tip Reporter big win in GWHP and AIKI we may see some serious happenings on FDIT. Way to go OTC Tip Reporter.
https://www.goldmanresearch.com/202008281284/Opportunity-Research/the-next-major-covid-19-player.html
https://www.goldmanresearch.com/202009251288/Opportunity-Research/the-next-great-social-media-co.html
BIG NEWS NO COVERAGE OTHER THAN THE RELEASE
Global WholeHealth Partners Corp (GWHP-OTC) to Announce that the Antibody Test Kits Offered by Global Can Detect the Mutated COVID-19 Strain
https://finance.yahoo.com/news/global-wholehealth-partners-corp-gwhp-113000503.html
This just came out from OTC Tip Reporter Do you see (NASDAQ: AIKI) right now?
As I write this, buyers are coming in during aftermarket trading, note AIKI traded between $1.03 and $1.12 today, and closed at $1.10.
As I write this, I'm watching AIKI trade right now in after-market hours between $1.30 and $1.35/share.
Wednesday could be potentially a gigantic day for AIKI investors.
If you haven't taken a look at this stock yet, this is your chance. AIKI is witnessing a major momentum run.
The Company has several bullish catalysts on the horizon, and is on the verge of disrupting a $176BIL Anti-Cancer Therapeutics Market, and Recent Blockbuster News AIKI Executes Licensing Agreement for Psilocybin for Cancer Applications.
Sincerely,
Editor In Chief, OTCtipReporter Team
COVERAGE BY OTC TIP REPORTER New Pick (Inside) Disrupts "$1TRL Crypto" Market with Worlds First Scalable Digital Cryptocurrency For Social Networks!
They send out alerts via email. The link below is to the website to sign up.
https://www.otctipreporter.com/
Whiskey, Bourbon, Vodka, Gin All Find Their Inspiration And Roots In The Historical Culture Of Texas
WATERLOO, ON / ACCESSWIRE / January 19, 2021 / SponsorsOne Inc., (CSE:SPO)(Frankfurt:5SO)(OTC PINK:SPONF), a company that utilizes its proprietary platform that combines digital marketing, wholesale and retail distribution, branding, and operational & funding capital, giving it a competitive first-mover advantage in rapidly selling proprietary brands focused in the Alcohol, Functional Beverage and Hemp Sectors, announced today the branding for its portfolio of distilled spirits.
https://finance.yahoo.com/news/sponsorsone-announces-branding-recently-revealed-134000731.html
Global WholeHealth Partners, Corp (OTC: GWHP) Announces New Purchase Agreement From RyZac Health as Order Size Increases Over 3 Times
https://finance.yahoo.com/news/global-wholehealth-partners-corp-otc-120000702.html
Investment Research Analyst Issued Analyst Coverage on
Global WholeHealth Partners Issuing a $11.20/share Price Target,
Representing 2,053% in Upside Potential!
Dear Fellow Trader,
Immediately turn your attention to Global WholeHealth Partners (GWHP)
This is our next "pandemic" related stock ready to move in a major way, here's why...
The street is taking notice of this emerging player in the hyper-growth Diagnostics & Research space!
Headlines about the global health crisis continues to dominate as the "New COVID-19 Strain" Spreads Across the country.
Strain found in Colorado, California, Florida, Georgia, New York
On January 5, Georgia authorities said the strain was detected in an 18-year-old resident with no travel history. A day earlier, New York said its first case was found in a 60-year-old man who also had not traveled. Days earlier, California officials reported six cases within the state: two in the same household in the Big Bear area east of Los Angeles and four in San Diego County. (One of the two Big Bear patients had contact with a person who returned from the U.K.) On December 31, Florida health officials confirmed that a man in his 20s with no history of traveling had tested positive for the new COVID strain. The first U.S. cases were identified in Colorado in late December.
With no signs of the virus slowing down yet, the demand for health defense products has been skyrocketing!
And that brings me to my newest profile, which could easily dish out some of the BIGGEST GAINS of 2021 with its 2,096% in upside potential!
Ready to get in on the ground floor of a medical company that distributes COVID-19 rapid diagnostic test kits?
Several Wall Street analysts have a strong buy & price target that is 2,096% higher than the current price. See this here before the crowd jumps in
This report right here will give you information about the company name, ticker symbol, and the full analyst report predicting 2,096% gains.
You need to see for yourself why several analysts predict this tiny medical company could potentially skyrocket in 2021…
But you have to act fast because this stock could become a media darling based on the potential FDA approval they are waiting for.
Investors who get in now, could grab themselves a potential 2,096% in gains based on Goldman Research's recent price target - See Below:
http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=537722&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8
Dear Fellow Trader,
I want to keep this short because the opportunity is moving fast.
Ready to get in on the ground floor of a medical company that manufactures and distributes COVID-19 rapid diagnostic test kits?
Several Wall Street analysts have a strong buy & price target that is 2,096% higher than the current price. See this here before the crowd jumps in
This report right here will give you information about the company name, ticker symbol, and the full analyst report predicting 2,096% gains.
You need to see for yourself why several analysts predict this tiny medical company could potentially skyrocket in 2021…
Investors who get in now, could grab themselves a potential 2,096% in gains based on the research report that Rob Goldman recently released right here
But you have to act fast because this stock could become a media darling based on the FDA approval they are waiting for.
If you go here now, I'll walk you through the analyst research on this rapidly-developing opportunity.
And I predict that this revolutionary company could be potentially at the center of it all.
I want to share with you its name and ticker symbol found here
Sincerely,
Editor In Chief, OTCtipReporter Team
http://www.icontact-archive.com/archive?c=865021&f=14629&s=19386&m=537722&t=06648922036e02f7f04a2684ef5de698b9328bbc84174897a2dc6366aad296b8
Global Whole Health Partners Corp. (GWHP) Announces It now offers the new FDA cleared "Fingerstick" for rapid COVID-19 test results in minutes
https://www.marketwatch.com/press-release/global-whole-health-partners-corp-gwhp-announces-it-now-offers-the-new-fda-cleared-fingerstick-for-rapid-covid-19-test-results-in-minutes-2020-11-05
New Report out. Goldman Small Cap Research Issues New Research Update on Global WholeHealth Partners Corporation. 12 Month Target they Have is $11.20
https://finance.yahoo.com/news/goldman-small-cap-research-issues-212500515.html
https://www.goldmanresearch.com/202101071299/Opportunity-Research/a-top-covid-10-diagnostics-stock.html
AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications
Wed, January 6, 2021, 8:00 AM EST
NEW YORK, Jan. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.
https://finance.yahoo.com/news/aikido-pharma-inc-executes-licensing-130000571.html
BIOTECH BREAKOUT REPORT
NASDAQ ALERT: AIkido Pharma Inc. (AIKI)
Can (AIKI) Run +2,701.76% Like 2020’s Biggest Biotech Win·ner?
Dear Fellow Trader,
Immediately turn your attention to AIkido Pharma Inc. (AIKI)
AIkido Pharma Inc. (AIKI) is an Artificial Intelligence-Cancer Fighting-Biotech
Company Like You’ve Never Seen Before.
My next alert is headquartered in one of the most affluent and highly educated communities in the United States--Bethesda, Maryland located in Montgomery County.
Is this by chance OR is there Strategic Reasoning for this Location?
You see, the Biotechnology industry in Montgomery County was born out of the Federal Research Laboratories at the National Institutes of Health, Food and Drug Administration (FDA), Walter Reed Army Institute of Research, the Uniformed Services University of the Health Sciences, and the National Institute of Standards and Technology (NIST).
These Federal Labs provide a critical mass Bioscience Labor Force, including Scientists who become entrepreneurs and founders of Biotech Firms.
Which brings us to our Biotech Breakout Alert: AIkido Pharma Inc. (AIKI)
Keep reading and You will see Exactly Why I am SO Excited about This Company.
?AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The Spherix platform contains patented technology from leading universities and researchers which seek to develop their innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Their diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Their pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Their AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, they are constantly seeking to grow their pipe to treat unmet medical needs in oncology.
Let’s Dive in Deeper on AIkido Pharma Inc’s
Financials and Science behind the Company
?Source: SEC Filing
Over $28 Million as of June 30, 2020 - No Debt
?Inves·tment Highlights
• We are a drug development company partnering with universities to treat cancer and viral infections
• Strong Balance Sheet: Over $28 Million as of June 30, 2020 - No Debt - Nominal Outstanding Warrants
• Market Oppor·tunities: DHA - dFdC (Gem - DHA) for oral and/or IV cancer treatment licensed from UT at Austin:
• Global gemcitabine market expected to reach >$900M by 2027
• CAGR of nearly 7% from 2019 to 2027
• Source: Transparency Market Research Pan - Viral Drug Design licensed from University of Maryland at Baltimore:
• Preliminary proof of concept against coronavirus, flu, Ebola and others
• Global flu drug market alone projected to reach $993.7M by 2026, with a CAGR of 2.2%
• Source: Fortune Business Insights Solid tumor drug (G4 - 1) optioned from University of Kentucky and SRA funded by Aikido:
• The global solid tumor cancer treatment market was valued at $121.3B in 2018
• Expected to reach $ 424.6B by 2027 with CAGR of 15.0% from 2019 to 2027
Anticancer Therapy DHA - dFdC (Gem - DHA)
Licensed to drug and novel oral formulation; published proof of concept in mice
General Strategy: develop to a logical, profi·table monetization exit point
Manufacturing optimization well underway. We have hired:
• Regulatory experts to assist in pursuing the FDA’s 505(b)(2) approval pathway
• Contract manufacturing organization (CMO) for manufacturing, formulation, optimization
• Chemistry, manufacturing, controls (CMC) firm for oversight of CMO, ensuring quality per FDA regs, developing chemistry research plan and formulation development/optimization, FDA required facility audits
Current Status:
• CMO optimizing manufacture of Gem - DHA; positive results so far
• Formulation development to begin thereafter; both oral and IV formulations pursued in parallel
• Limited animal testing to begin in the latter stages of formulation development
• Will hire on contract research organization (CRO) for animal testing soon
• Pre - IND meeting with FDA anticipated Q1 or Q2 2021 depending on formulation results
Anticancer Therapy DHA - dFdC
Derivative of FDA - approved chemo drug gemcitabine
• Gem - DHA drug patent recently issued; expires 2035
• Solid lipid nanoparticles (SLNs) used for oral delivery
• Oral formulation patent application filed in June 2020
• Better activity than gemcitabine
• Safety profile promising in mice
• Greatly reduces drug resistance
• Unexpectedly concentrates in pancreas
UMB Antiviral Program
Pan - Viral Treatment Design – Corona, Influenza, Ebola
• We have licensed and funded an SRA ($3M over 2 yr ) to discover new computer - designed panviral treatments
• License includes patent applications on several candidates
• Nonprovisional patent application filed in June 2020
• SRA funds optimization of licensed candidates
• Lead scientist is well - known virologist Matthew B. Frieman, Ph.D.
• Dr. Frieman is working to identify novel and repurposed drugs,
antibodies and vaccines for Influenza virus, SARS - CoV , MERS - CoV and
SARS - CoV - 2 inhibition
• Source: https://www.medschool.umaryland.edu/profiles/Frieman - Matthew/
• We are working to increase our relationship with UMB and Dr. Frieman and add to our participation as oppor·tunities arise.
UMB Antiviral Program
• SKI complex ID’d as a potential broad - spectrum antiviral target
• Initial data suggested functional link between viral proteins and SKI
• Computer modeling ID’d potential drug binding pockets on SKI
• Computer modeling to design compounds to bind SKI pockets
• Screening ID’d specific compounds that inhibit various viruses
• Inhibited viruses include influenza, Ebola and Corona Pan
UK G4 - 1 for Solid Tumor Treatment
• Option to license and $67.5K SRA to study 30 - day survival in mice
vs. competitor drugs
• First option allowed to lapse in favor of funding this study in exchange for another option
• Option lasts until 45 days after results reported to us (extendable)
• Computer - designed drug isolated from ~340,000 candidates
• Effective against solid tumors, unlike competitors
• Excellent metabolic stability profile relative to competitors
• Works in cancers already resistant to competitor drugs
• Patent subject to our Option expires 2035
Machine Learning Project with UTSW
• Focus on stages of pancreatic ductal adenocarcinoma
• Time and materials SRA with UTSW with max of $152K
• Further agreement with BCII Biotech Ltd. ($150K total)
• Sister company to Cogia Biotech, a big - data, AI/ML company using AI algorithms in drug development *
• Assist in developing AI and ML iterative models
• Determine specific markers from six stages of PDA
?• To date, 2762 candidate markers screened and 120 best markers identified in 5 cell types
Wakeforest’s KPC34 for AML and ALL
• Licensed to KPC34 for treatment of AML and ALL
• Small target patient populations:
• Acute Myeloid Leukemia (AML) (~21K new/ yr )
• Acute Lymphoid Leukemia (~6K/ yr )
• Eligible for Orphan Drug Designation, providing 7 years market exclusivity
• Global market:
•AML: $701.6M in 2018, $1.54B (est.) in 2024, CAGR 14.0%
•ALL: $2.3M in 2018, $3.5M (est.) by 2026, CAGR 5.3%
Additional Research and Due Diligence:
AIkido Pharma Inc. (AIKI) Has Strong Partnerships with World Renowned Institutions, such as The University of Texas.
As I was doing my research and due diligence, I found 2X Very Interesting Facts about The University of Texas and How This Could Be a Potential Catalyst For Our Profiled Company: AIkido Pharma (AIKI).
?1. The Current Commissioner of the FDA has ties to the University of Texas.
Prior to joining the FDA, Dr. Hahn served as the chief medical executive (CME) at The University of Texas MD Anderson Cancer Center, a facility that cares for more than 140,000 patients a year. He has proven executive leadership that spans research, development, clinical trials, patient care, health system management and education. In his role as CME, he was responsible for day-to-day management of the institution, including business, clinical and faculty matters.
Why is this important to AIkido Pharma Inc?
You see, the FDA is the Ultimate Gatekeeper. As the regulatory body that approves new drugs for the U.S. market, as well as permitting human clinical trials, the Food and Drug Administration (FDA) is the ultimate gatekeeper for every biotech firm. The FDA requires that all companies establish to its satisfaction that a potential new drug is safe and effective for its stated purpose.
Investors need to understand the FDA process and requirements. In order to get FDA approval, Biotechs must establish a sufficient body of information that the drug is safe and effective. This is generally done through a series of at least three clinical trials. AIkido Pharma Inc. has a strong relationship with The University of Texas...And the current FDA Commissioner just served as the Chief Medical Officer of The University of Texas. (You See what I’m Saying Here?)
The University of Texas has a history of Producing a Massive Biotech Success Story. You see, back in the early 1990’s a Chemist named Jonathan Sessler founded a pharmaceutical research company called Pharmacyclics. The company's aim was advancing molecules Sessler had engineered in his University of Texas at Austin laboratory to target cancer.
Pharmacyclics was eventually sold
to Abb bVie for $21B
Could AIkido Pharma Inc. (AIKI) Be Onto A Major Breakthrough
?With The University of Texas?
The Current FDA Commissioner was Just the Chief Medical Officer of The University of Texas.
AIkido Pharma Inc. (AIKI)
Recent News:
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the US. PDA is increasing in frequency owing to its association with obesity, smoking, and type 2 diabetes.
PDA treatment is severely compromised because most diagnoses are made late in disease progression. Surgical resection remains the most effective therapeutic strategy but is restricted to early-stage diagnosis and is rarely, if ever, curative. In spite of the decades of research and recent advances, the five-year survival rate has only improved to 9%, and less than 20% of patients survive one year.
Thus, there is a pressing need for systematic and robust screens to develop novel, effective PDA therapeutics for early-stage disease and after successful surgical resection to delay or prevent relapse. AIkido's strategy to identify better therapeutics is to screen drugs in primary cell culture, followed by validation in a mouse model of early disease progression.
November 13, 2020
Lead compounds have anti-coronavirus activity, including against SARS-CoV and SARS-CoV2
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The publication reports studies on newly discovered antiviral compounds that were developed using a computer modeling approach. The lead compounds were found to have broad-spectrum antiviral activity, inhibiting influenza virus, Ebola, Marburg, MERS-CoV, SARS-CoV, and SARS-CoV2, the virus that causes COVID-19.
Mr. Anthony Hayes, CEO of AIkido stated, "The results of this peer reviewed study provide encouraging data for Company's newly licensed compounds. I am particularly excited with the data that demonstrates inhibition of SARS-CoV2 by the lead compounds. This represents yet another solid validation of University of Maryland, Baltimore's (UMB) antiviral platform, to which we are the exclusive licensee. In addition, this article provides a significant amount of substantive information about the technology we have licensed from UMB. I encourage our shareholders who want more information about the technology to review the article."
The Company previously executed a Master License Agreement with UMB for specific antiviral compounds discovered by UMB that seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, SARS-CoV2, MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The Company previously executed a Sponsored Research Agreement with UMB to support the development of the technology.
October 28, 2020
AIkido Pharma Inc. Provides Update on Its Next-Generation
Chemotherapeutic Treatment DHA-dFdC
Synthesis of Critical Chemical Intermediate for Drug Confirmed
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer, which the Company has licensed from the University of Texas at Austin.
Pancreatic cancer is the 4th leading cause of cancer deaths in the US and, partly because most cases are diagnosed at an advanced stage, the 5-year overall survival rate for those cases has remained only around 3%.
The Company is developing its drug product as an orally administered second-line treatment to target advanced pancreatic cancer.
The Company confirmed this week the successful synthesis of a critical intermediate compound for DHA-dFdC. Purification and isolation of this key intermediate were also completed and verified.
The Company is also in the process of optimizing the SLN delivery vehicle with respect to particle size and stability.
In addition, the Company recently expanded upon its agreement with Parimer Scientific to immediately begin manufacturing activities including the following:
Developing analytical methods for both raw materials and final drug product,
Producing an optimized process for batch scale-up of the drug,
Producing and delivering 20,000 mg of final drug product to be used in toxicology studies,
Performing initial short-term and long-term stability testing in the selected bulk container closure using ICH Q1A(R2) Stability Testing of New Drug Substances and Products,
Creating a drug substance reference standard, and
Establishing drug purity per the relevant FDA standards.
Under the expanded agreement, the final drug product will be manufactured using at minimum GLP practices per 21 CFR 58 and following the recommendations in the FDA's ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
Dr. Richard T. Pace, Principal Scientist at Parimer Scientific commented, "We are very gratified to have confirmed isolation of the crucial chemical intermediate for this drug. These results strongly indicate that developing a scalable process for drug manufacture will be achievable."
Anthony Hayes, CEO of AIkido stated, "These are the results we have been hoping for and they greatly increase my optimism about the scalability of this product. We plan to rapidly develop the process of drug incorporation into the SLN delivery particles and start preliminary biological testing, which should begin this quarter."
Board of Directors & Management
Robert J. Vander Zanden, Ph.D.
Chairman of the Board
Dr. Robert J. Vander Zanden, Board Member since 2004, was elected Chairman of the Board in early 2009. Having served as a Vice President of R&D with Kraft Foods International, he brings a long and distinguished career in applied technology, product commercialization, and business knowledge of the food science industry to Spherix. In his 30-year career, he has been with ITT Continental Baking Company as a Product Development Scientist; with Ralston Purina’s Protein Technology Division as Manager Dietary Foods R&D; with Keebler as Group Director, Product and Process Development; with Grupo Gamesa, a Frito-Lay Company, as Vice President, Technology; and with Nabisco as Vice President of R&D for their International Division. With the acquisition of Nabisco by Kraft Foods, he became the Vice President of R&D for Kraft’s Latin American Division. Dr. Vander Zanden retired from Kraft Foods in 2004. He currently holds the title of Adjunct Professor and Lecturer in the Department of Food, Nutrition, and Packaging Sciences at Clemson University, where he also is a member of their Industry Advisory Board. His focus on achieving product and process innovation through training, team building and creating positive working environments has earned him multiple awards for product and packaging innovation. Dr. Vander Zanden holds a Ph.D. in Food Science and an M.S. in Inorganic Chemistry from Kansas State University, and a B.S. in Chemistry from the University of Wisconsin – Platteville, where he was named a Distinguished Alumnus in 2002.Tim Ledwick
Board Member
Mr. Ledwick is currently the Chief Financial Officer of Management Health Solutions, a private equity-backed company that provides software solutions and services to hospitals focused on reducing costs through superior inventory management practices. In addition, since 2012 he has served on the board and Chair of the Audit Committee of Telkonet, Inc. (TKOI) a smart energy management technology company. From 2007 to 2011, Mr. Ledwick provided CFO consulting services to a $150mm services firm and, in addition, from 2007-2008 also acted as special advisor to The Dellacorte Group, a middle market financial advisory firm focused on transactions between $100mm and $1B. From 2002 through 2006, Tim was a member of the Board of Directors and Executive Vice President-CFO of Dictaphone Corporation playing a lead role in developing a business plan which revitalized the company, resulting in the successful sale of the firm and delivering a seven times return to shareholders. From 2001-2002, Ledwick was brought on as CFO to lead the restructuring efforts of Lernout & Hauspie Speech Products, a Belgium-based NASDAQ listed speech technology company, whose market cap had at one point reached a high of $9B. From 1999 through 2001, he was CFO of Cross Media Marketing Corp, an $80 mm public company headquartered in New York City, playing a lead role in the firm’s acquisition activity, tax analysis and capital raising. Mr. Ledwick is a member of the Connecticut Society of Certified Public Accountants and received his BBA in Accounting from The George Washington University and his MS in Finance from Fairfield University.
Greg Blattner
Board Member
Greg Blattner is a Director at Agio, a progressive Managed IT and Cybersecurity Services Provider. A noted leader in the alternative inves·tment technology space, Greg developed his career building and maintaining superior technology and operations solutions for Wall Street firms during a time when the industry’s technological complexity and data dependency experienced rapid evolution. Prior to Agio, Greg held Business Development and Operations Management positions at Reuters, American Express, JPMorgan, Morgan Stanley and Deloitte. He received his undergraduate degree from Iona College in New York.
Anthony C. Hayes, Esq.
CEO
Anthony C. Hayes is the CEO of AIkido Pharma Inc., a NASDAQ-traded (ticker: AIKI) technology commercialization company. Hayes began his tenure by overseeing AIkido’s transformation from a biotechnology company into a diversified corporate entity, committed to advancing innovation by participating in the development of new technologies across several sectors.
As CEO, Hayes developed and implemented a strategic plan to advance AIkido’s mission and objectives and to significantly promote company growth. He identified and brought about multimillion-dollar M&A acquisitions that resulted in some of the largest transactions in technology patents. Hayes is also involved in all aspects of investor relations, representing AIkido in shareholder meetings, at domestic and international conferences, and in television and print media (such as Bloomberg Television and Forbes).
An attorney and former partner of an Am Law 100 firm, Hayes previously co-founded and was managing member of JaNSOME IP Management LLC, an intellectual property monetization firm. JaNSOME provided consulting and advisory services to individuals and companies on best practices for monetization of the asset class.
President George W. Bush gave Hayes special recognition for creating the Wills for Heroes program, a national 501(c)(3), in response to the September 11 attacks (willsforheroes.com). Other honors include IAM IP Personality of 2013, American Board of Trial Advocates Young Lawyer of the Year and “20 Under 40” in Columbia, South Carolina.
Education: Juris Doctor from Tulane University Law School (1995); Bachelor of Arts in economics from Mary Washington College (1990)
Bar Memberships: District of Columbia; Florida; New York; South Carolina
Publications: “Avoiding the Post-Crisis Crisis: How to Prevent Post-Crisis Donation for Victims from Leading to Litigation” (ICMA Journal, January/February 2008)
5 Reasons Why Investors Love Biotech Stocks Like
AIkido Pharma Inc. (AIKI)
1. Potential for Massive Breakout
Investing in the biotechnology industry can prove to be overwhelmingly lucrative. Most clinical-stage stocks in this sector trade at prices under $5 per share. However, the successful launch of a new treatment option can send the stock soaring. If there’s ever a sector that creates milli·onaires, biotechnology is it.
2. The Feel-Good Effect
These days, investors make inves·tments for more than profit. In fact, there’s a trend of socially responsible investing sweeping the globe. With socially responsible investing, you look for and invest in companies that are making positive change in the world.
Some socially responsible investors look toward solar stocks for environmental change or financial-literacy stocks designed to remove the wealth divide. Others invest in biotech stocks, helping to fund the development of life-saving and life-changing treatment options. That’s something to feel good about. Cancer is one of the leading death-causing diseases... You probably know someone who has it.
3. Better Understanding of Medicine
When investing in any stock in any sector, it’s important to do your research. When doing this due diligence in the biotech industry, you’ll learn quite a bit about the human body, medicine, and the various ailments medicines are being designed to treat and cure. Scroll back through this report when you have time. You'd be ama·zed at some of the technology that AIkido Pharma Inc. has access to.
4. Interest in the Industry
Never before have so many eyes been on the biotech industry. The race is still on for a treatment or vaccine for COVID-19, the illness caused by the new coronavirus, and biotech companies are at the forefront.
5.High Chance for Acquisition
Since 2018, I counted 63 acquisitions of biotech companies based off this awesome list from Index. If you have ever had a stock get acquired, you know that there likely is going to be a Major Pop in share price as soon as that acquisition is announced, which is great for the owners of that company.
2020 was a Great Year for Biotech Inves·tors and Analysts
are Predicting 2021 Could be Even Bigger.
If you had bought NVAX in 2020, a $5K inves·tment could have turned into a Staggering $135K.
Could AIkido Pharma Inc. (NASDAQ: AIKI) Run +2,701.76% and be
Your Next Potential Massive Breakout?
Below are the 10 Best Performing Biotech Stocks of 2020
Catalyst for AIkido Pharma Inc. (AIKI) That Could
Send Shares Soaring This Week.
1. Strong Balance Sheet: Over $28 Million - Debt Free.
2. Currently Partnering and Building Strong Relationships with Major Universities.
3. Participating in the Flu Drug Market - Projected to $993.7M by 2026.
4. Participating in the solid tumor cancer treatment market - Expected to reach $424B 2027.
5. Biotechs provide Potential for Massive Profits, like NVAX that ran +2,701.76% in 2020.
6. An FDA Approval or positive feedback could send shares of AIKI through the roof.
7. AIKI and their team of partners are working on Breakthrough Artificial Intelligence for detecting Pancreatic Cancer -- any news, press releases or updates on this could cause the shares to go Parabolic.
Another big catalyst that could potentially send shares breaking out higher is Wall Streets leading provider of market data Barchart, which upgraded AIKI to a 80% Buy rating short-term, 100% Buy rating medium-term, 33% Buy rating long-term.
Barchart just Triggered 11 out of 12 Buy Signals across the short-term indicators, medium-term indicators and even the long-term indicators - See Below:
I strongly suggest you read the technicals immediately to learn why AIKI has the potential to breakout!
I strongly suggest you click here and read the technicals immediately to learn why AIKI has the potential to breakout!
Do Not Wait on AIKI this week, Recent Volume Increases Could be Indicating that a Massive Run Could be Coming…
Like I mentioned above, AIkido Pharma Inc. (AIKI) is Headquartered in close proximity to the FDA’s Headquarters in Maryland, AIkido Pharma Inc. has a Strong Partnership in place with The University of Texas, the new FDA’s Commissioner came from his position as the Chief Medical Officer at The University of Texas. Are there some synergies here that could massively benefit AIkido Pharma Inc. (AIKI) ? The Research Analyst in me seems to think so.
Pull Up AIKI (Right Now)... If AIKI makes a +2,701.76% Massive Run, You are going to hate yourself for missing out.
You need to be ready first thing this morning.
Pull up AIKI on your screen right now and start your research.
?Sincerely,
?Editor In Chief, OTCtipReporter Team
https://www.fdctech.com/download/FDC_Investor_Deck.pdf
FDCTECH, INC.
A Fully Custom-Branded
Trading Technology Infrastructure
for the Largest Market in the World
SEPTEMBER 2020
Disclaimer
This presentation is prepared exclusively for the benefit and internal use of ACCREDITED INVESTOR(S) as defined under the Securities Act of 1933 to whom it is directly addressed and delivered. This presentation is for discussion purposes only and is incomplete without reference to, and viewed solely in conjunction with, the oral briefing provided by FDCTech, Inc. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company. This presentation contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. All forecasts are provided by management in this presentation and are based on information available to us at this time and management expects that internal projections and expectations may change over time. Also, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current growth opportunities and conversations with new and existing customers about our FX solutions.
Breaking News 27 "Cryptos" Just Hit All-Time Highs!
You Need to Pull Up FDCT (Right Now) Cryptos Are Going Nuts at This Very Moment.
The Exchanges and Service Providers (like FDTC) Will Benefit Either Direction
the Coins Move - The House Always Wins!
Dear Fellow Trader,
Immediately turn your attention to FDCTech Inc. (FDCT)
I have been saying it all weekend. Pull up FDCT (Right Now)
There is a Massive Shift into Cryptos This Weekend, we are in the midst of another Crypto Frenzy and companies like FDCT Have the Potential to Make Serious Moves This Week.
Bitcoin Blasts Past $34K for First Time,
Hours After Blowing Through $30K
The price of bitcoin (BTC) surged past $34,000 for the first time ever early Sunday morning, extending a record-setting holiday rally and adding an immediate exclamation point to the Bitcoin Network’s 12 year anniversary.
Bitcoin was trading hands around $34,400 at 02:30 EST Sunday. Hours earlier, the leading cryptocurrency had sliced through $30,000 like a light saber through gossamer, a torrid start to the year.
Once the price of the leading cryptocurrency crossed the $30,000 mark for the first time — it exploded upwards like a ball released under water, reaching a new all-time high of $33,136.92 and then continuing the push, breaching $34,000 hours later.
“Bitcoin makes TSLA (Tesla) look like it is standing still,” tweeted Jim Bianco, well-known macro strategist, shortly after the cryptocurrency broke $30,000.
The latest gains come two days after bitcoin closed out a year in which the cryptocurrency rose more than 300%, with an almost 50% gain in December alone, sort of like a boulder gaining speed downhill, only in the opposite direction. On Nov. 30, bitcoin breeched a nearly three-year-old high of $19,793. By the close of Dec. 31, the cryptocurrency had risen about $10,000.
Propelling the record-setting run is a growing narrative that bitcoin represents a form of “digital gold,” along with a flood of institutional investors into the cryptocurrency: Among them: Anthony Scaramucci’s Skybridge Capital ($182MIL in December); MassMutual ($100MIL in December); and Guggenheim (up to 10% of its $5BIL macro fund).
“Bitcoin price is being driven by institutional money and there is not enough supply,” Laurent Kssis, managing director at 21Shares, told CoinDesk. “The number of family offices asking to invest in our ETP is just staggering. I’ve never seen this before. In 2017 it was just retail knocking at the door now it’s only institutional.”
Kssis’ statements are borne out by the fact that the number of whale entities – clusters of crypto wallet addresses held by a single network participant holding at least 1,000 bitcoin – rose to a new record high of 1,994 this past Wednesday.
The metric increased by over 16% in 2020 and 7.3% in Q4 alone.
“The final land grab has started, and by this time next year, accumulating >1,000 Bitcoin will be nearly impossible for most people,” Jehan Chu, CEO at Hong Kong-based trading firm Keneti Capital, told CoinDesk.
With a market value now of over $595BIL, bitcoin is more valuable than all but nine publicly traded companies, sitting between Alibaba at $648.3BIL and Berkshire Hathaway at $543.7BIL.
Bitcoin enthusiasts will likely find some joy in that last bit, an event that occurred last week, as the Berkshire’s CEO, legendary investor Warren Buffett, once famously derided bitcoin as “probably rat poison squared.”
The cryptocurrency has also rose up the ranks of the world’s most valuable currencies, overtaking the Saudi Riyal into 17th place, just behind the Mexican Peso.
And timing couldn’t be any better!
I have been saying it all weekend. Pull up FDCT (Right Now)
There is a Massive Shift into Cryptos This Weekend, we are in the midst of another Crypto Frenzy and Companies like FDCT Have the Potential to Make Serious Moves This Week.
Stocks are set to enter the new year at a record high when the first day of trading for 2021 kicks off Monday. Crypto’s Relentless Rally Explodes to All Time High.
FDCTech (FDCT) Operates in the Massive FX Market-Cryptocurrency,
Blockchain Space Which Sees Over $6.6Tril Daily Volume!
With a full suite of FX and Crypto technology and business solu·tions, FDCTech (FDCT), the company’s flagship product is the Condor FX Pro Trading platform, which is a fully customizable multi-asset trading platform for forex, crypto, stocks, and commodities.
This market offers Many Growth and Expansion Possibilities for FDCTech (FDCT) to Grow Revenue and Drive Shareholder Value:
Why FDCTech Inc. (FDCT) Exists?
To Solve Industry Problems
FDC’s retail FX trading market is $400Bil in daily trading volume. Over 3Mil active traders access the FX market daily through over 2,000 FX Brokers worldwide.
The development of a proprietary multi-asset trading platform is complicated & expensive. Currently 20 large FX brokers have proprietary trading platforms.
Medium to small FX Brokers have a limited budget for dedicated IT and software teams. They manage several third-party technology vendors.
Most FX Brokers access the interbank FX market through FX Prime and FX Prime of Prime (FX PoP) Brokerages via third-party technology providers.
Now Enter FDCTech Inc. (FDCT) and Their Solutions!
FDC offers Condor FX Pro – a fully customizable multi-asset trading platform, back-office, CRM, and FX business solu·tions to FX brokers.
Through the sale of FDC’s basic source code, FX Brokers can customize and brand the platform as a proprietary Offering.
FDC develops all components of technology infrastructure in-house and assigns a dedicated team to each FX broker.
FDC offers a full suite of FX PoP technology infrastructure and business solu·tions at a competitive price. This allows FX PoP to use the principal model.
Keep reading to learn more about FDCTech, Inc. (FDCT), their management team and recent news.
FDCTech delivers trading platforms, back-office, liquidity, dealing desk, and prime brokerage solu·tions to forex market participants looking to access the retail and institutional spot forex mar·kets.
FDC's business solu·tions enable brokers to boost sales, cut costs, seize chances, and anticipate challenges like never before.
FDC provides innovative and cost-efficient financial technology (FinTech) and business solu·tions to OTC Online Brokerages and cryptocurrency businesses.
The Company's products are designed to provide a complete solu·tion for all operating aspects of customer's business, including but not limited to trading terminal, back office, customer relationship management, and risk management systems.
The Company provides business and management consulting, which include management consulting and the development of customers' B2B sales and marketing divisions.
FDC combines their senior management experience in running forex businesses and the software team's expertise, which has 15+ years of knowledge in developing capital mar·kets software solu·tions.
Meet the C-Suite Management Team & Directors
that Lead FDCTech (FDCT)
CEO & FOUNDER | DIRECTOR
MITCH EAGLSTEIN
From January 2016 to date, Mr. Eaglstein is the Founder, Chief Executive Officer and Director of FDCTech, Inc. Mr. Eaglstein is responsible for developing and implementing the Company's overall corporate strategy. He has extensive executive-level experience in the management of FX brokerage and FinTech software companies.
Mr. Eaglstein led a Dubai based FX Company from pre-revenue to $45Mil in annualized trading revenue within one year from the start-up date. Under his leadership, the Company exceeded $50Bil in monthly trading volume within one year ranked in the top 20 forex brokers' globally by volume. He was instrumental in increasing revenue of Boston Technologies from $5Mil to $20Mil, thus making it the 143rd fastest-growing Company in America by Inc. 500 ranking.
CFO & FOUNDER | DIRECTOR
IMRAN FIROZ
From January 2016 to date, Mr. Firoz is the Co-Founder, Chief Financial Officer and Director of FDCTech, Inc. Mr. Firoz is responsible for strategic planning & corporate development, M&A, financial restructuring and risk-management. He has been responsible for guiding due diligence efforts, implementing financial controls, putting in practice compliance guidelines and planning disaster recovery strategy.
Mr. Firoz received his MBA in April 2001 from Richard Ivey School of Business, University of Western Ontario, Canada and graduated in July 1993 with Bachelor of Engineering (Chemical) from Aligarh University, India. Mr. Firoz is a Certified Financial Risk Manager from the Global Association of Risk Professionals.
CHIEF OPERATING OFFICER
PEGGY S. REED
Ms. Reed joined FDCTech, Inc. in August 2016 as its Chief Operating Officer. As COO, Ms. Reed is leading the Company's operations with the primary focus on scaling customer base, managing customers, and expanding operations globally.
Ms. Reed is an experienced professional in the financial services industry for over eighteen years. Ms. Reed is overseeing the Company's sales, marketing, and business development strategy. Ms. Reed received a degree in 1983 in Economics from USC.
CHIEF TECHNOLOGY OFFICER
BRIAN D. PLATT
Mr. Platt joined FDCTech, Inc. in May 2016. Mr. Platt has over ten years’ experience in the FX industry managing complex technology and business operations. His expertise includes advanced technical knowledge of databases, programming, and product development life cycles as well as a clear understanding of business needs. Mr. Platt’s passion is combining this business and technical knowhow to assure the best products, client satisfaction, and optimization of human resources.
Company Highlights and Revenue Generating Activities
At Present, the Company Has Three Sources of Revenue
Consulting Services – The Company’s turnkey business solu·tions - Start-Your-Own-Brokerage (“SYOB”), Start-Your-Own-Prime Brokerage (“SYOPB”), Start-Your-Own-Crypto Exchange (“SYOC”), FX/OTC liquidity solu·tions, and lead generations.
Technology Solu·tions – The Company licenses its proprietary and, in some cases, act as a reseller of third-party technologies to customers. Our proprietary technology includes but is not limited to Condor Risk Management Back Office (“Condor Risk Management”), Condor FX Pro Trading Terminal, Condor Pricing Engine, Crypto Web Trader Platform, and other cryptocurrency-related solu·tions.
Customized Software Development – The Company develops software for Customers with unique requirements as outlined in the Software Development Agreement (“Agreement.”)
Additional Licensing and Reseller Growth Oppor·tunities!
In the retail foreign exchange trading space where individuals speculate on the exchange rate between different currencies, our customers are forex brokerages, prime of prime brokers, prime brokers, and banks.
The Company generates revenues by licensing its trading technology infrastructure, including but not limited to the trading platform (desktop, web, mobile), back office, and CRM and banking integration technology.
FDC acts as an adviser/strategic consultant and reseller of its proprietary technologies in the cryptocurrency and blockchain space.
The Company expects to generate additional revenue from its crypto-related solutions, such as from the development of custom crypto exchange platform for customers, the sale of the non-exclusive source code of crypto exchange platform to third parties, white-label fees of crypto exchange platforms, and the sale of aggregated cryptocurrency data price feed from various crypto exchanges to OTC brokers.
The Company initially plans to develop the technology architecture of the crypto exchange platform for its customers. The initial capital required to produce such technologies comes from our customers as the Company takes on design-build software development projects for customers.
FDC develops these projects to meet the design criteria and performance requirements as specified by the customer.
There are several steps required to set-up a functional crypto exchange platform.
FDC’s customers seek necessary licensing approval and meet registration requirements in their respective jurisdictions.
FDC’s Customers are also responsible for establishing a relationship with the payment processing partner, such as a bank. Subsequently, the Company intends to provide and maintain a payment gateway API, giving users the power to add and withdraw funds.
Liquidity is an essential aspect of the success of a cryptocurrency exchange marketplace. The trades at an exchange drive its liquidity, and a robust crypto exchange platform requires seamless trading activity.
To manage this liquidity at the customer’s crypto exchange business, the Company will integrate its customer crypto exchange’s liquidity position to other existing exchanges.
FDC will provide a modern and robust API interface that connects liquidity and trade volume data between various crypto exchanges.
RECENT NEWS:
December 20th, 2020
IS Prime Offers Liquidity Via FDCTech (FDCT)
Condor FX Pro Trading Platform
Irvine, CA, Dec. 22, 2020 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," OTCQB: FDCT), a fintech company with a full suite of FX technology and business solu·tions, today announced that IS Prime, part of ISAM Capital Markets, has partnered with FDC to extend its liquidity distribution to the innovative Condor FX Pro Trading Platform.
Condor FX Pro Trading Platform is FDC's flagship product. It provides a complete trading suite for retail brokers, fund managers, and traders with proprietary charting tools, advanced order types, level II pricing, multi-tier margin management, and regulatory reporting tools.
Barry Flanigan, Head of Distribution and Liquidity, IS Prime, comments, "A number of our clients use FDC as a front-to-back solu·tion, and it is important for us to connect with the platforms our clients choose to use. Condor FX Pro Trading Platform is a relatively new platform which is rapidly gaining traction globally, and this partnership will extend our client reach, giving FDC clients the oppor·tunity to have easy access to our highly competitive multi-asset liquidity."
FDC's CEO, Mitchell M. Eaglstein, adds, "We are very proud to be working with a company as reputable as IS Prime and to offer its liquidity to our growing client base."
December 20th, 2020
FDCTech teams up with GC Exchange Limited to provide 24/7 institutional liquidity and trading technology infrastructure to FX and Crypto Brokerages
Irvine, CA, Dec. 10, 2020 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," OTCQB: FDCT), a fintech company with a full suite of FX technology and business solu·tions, today announced that GC Exchange Limited, doing business as 'GCEX' has partnered with FDC to provide 24-hour crypto trading and tier 1 FX and crypto liquidity using FDC's Condor FX Pro Trading Platform, a fully customizable trading platform compared to legacy off-the-shelf trading platforms. GCEX is authorized and regulated by the Financial Conduct Authority, FCA (FRN 828730).
FDC's Condor FX Pro Trading Platform covers the whole spectrum of needs of any FX or Crypto Broker. Firstly, it can be deployed as an off-the-shelf trading platform to enable FX and Crypto brokers to become fully operational within days.
Secondly, it allows for the platform's full customizability from the back-end configurations to the front-end user interface to other structural adjustments, thus eliminating several third-party technology vendors' requirements. Coupled with GCEX liquidity, Condor FX Pro Trading Platform provides a 24-hour trading environment 7-days a week for crypto and forex traders.
GCEX's CEO and Founder, Lars Holst, an industry pioneer since 2000, said, "As mar·ket volatility continues to drive FX and crypto trading volumes, we believe a robust but flexible trading technology infrastructure is vital to capitalize on this trend. By partnering with FDC, we have ensured that we can deliver a world-class trading experience where brokers can access our tier 1 FX and crypto liquidity."
FDC's Chief Executive Officer, Mitchell M. Eaglstein, stated, "GCEX is the leading source of multi-asset liquidity for brokers worldwide. Moreover, GCEX's team has in-depth business experience building successful global FX brokerages over the last two decades. By adding FDC's trading platform and software development expertise, GCEX can provide turn-key and affordable solu·tions for entrants looking to access FX and crypto mar·kets."
7 Catalysts That Could Potentially Send FDCT
Shares Soaring This Week
Catalyst #1: Fintech Sector is on fire and driving massive potential gains for investors, (Square Inc. saw Triple Digit Gains in 1 less than year.)
Catalyst #2: Huge Growth Potential in Crypto/FX Mar·ket.
Catalyst #3: Talent Stacked Management Team with over 30 years Business experience in the FX space. 15+ Years FX Development Experience, with Crypto and Blockchain capabilities.
Catalyst #4: Company Just Signed a New Liquidity Distribution Deal with IS Prime to extend onto Condor Platform.
Catalyst #5: Company Signed Recent Deal with GC Exchange to Provide 24/7 Crypto Trading on FDC’s Condor Platform.
Catalyst #6: FDCTech Inc. (FDCT) has a history of +478.95% runs and could be setting up for another one (This Week)
Catalyst #7: FDCTech, Inc. is a small company that is currently flying under the RADAR, once Wall Street picks up on FDCT, there is no-telling what could happen.
I am bringing FDCT to you first.
Do not wait on FDCT.
You do not want to miss out on another +478.95% Potential Run!
If you've missed out on the +58.32% gains that my last alert just provided, then don't miss FDCT.
Let me remind you...I first initiated coverage on my previous alert back in June, and for those of you who have been following it since then have seen some wild swings...a Big Congrats to those of you who played the swings, you've made out well.
Take a look at the chart below on my previous alert from last week, I’ve highlighted its swings each month since my initial alert back in June:
It's time for you to grab hold to another potential 100%, 200% or even 500% gainer.
I've been searching for another explosive breakout stock like your previous big pick which went gangbusters running up +334.99% from my alert back in June.
If you liked your previous pick above that I just mentioned, I believe you are going to love your NEXT New Breakout Stock for Monday FDCT.
So, without wasting any more time, don't delay and pull up FDCT on your trading screen before you miss out on another potential winner, with tremendous upside potential.
I am urging all of my members to add FDCT to the top of their watch list right now, and be ready Monday morning at the opening bell!
MarketCaliber
Trading Research Team
Sources:
https://www.fool.com/investing/stock-market/market-sectors/financials/fintech-stocks/
https://www.fdctech.com/download/FDC_Investor_Deck.pdf
https://www.otcshortreport.com/company/FDCT
Dec 31 NA NA NA 4,225 4,000 94.67
Dec 30 NA NA NA 5,065 1,238 24.44
Dec 29 NA NA NA 8,815 8,765 99.43
Dec 28 NA NA NA 24,150 6,550 27.12
Dec 24 NA NA NA 3,000 3,000 100.00
Dec 23 NA NA NA 169,188 140,026 82.76
Dec 22 NA NA NA 97,568 91,536 93.82
Dec 21 NA NA NA 66,366 36,468 54.95
Dec 18 NA NA NA 120,629 62,722 52.00
Dec 17 NA NA NA 17,518 3,218 18.37
Dec 16 NA NA NA 60,754 36,054 59.34
Dec 15 NA NA NA 35,380 10,833 30.62
Dec 14 NA NA NA 69,928 32,601 46.62
Dec 11 NA NA NA 237,313 135,063 56.91
Dec 10 NA NA NA 86,912 80,490 92.61
Dec 09 NA NA NA 129,256 89,133 68.96
Dec 08 NA NA NA 230,440 55,416 24.05
Findit is doing videos for members on the platform. They look good.
https://www.youtube.com/channel/UCNpzUswz6mcDY3Socl8Y-kg/videos
Noticed they are doing marketing of the actual products they offer. Nice to see the company focusing on sales.
Check out the videos
Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off One of Its Outstanding Convertible Notes
https://news.findit.com/news/1812967/global-wholehealth-partners-corp-otc-gwhp-has-paid-off-one-of-its
FDIT Barchart Technical Opinion Rating
Triggered 11 out of 12 Possible Buy Signals
Dear Fellow Trader,
FDIT is breaking out to the upside very fast hitting a high of $.148 yesterday up +34.66% from my alert at Monday's open!
Pull up FDIT and look at the +183.70% multi-day run from 9/28 to 10/01, when it hit a 52-week high of $.2525/share.
FDIT could be at the beginning stage of another Massive Run back to its 52-week high.
FDIT RSI (Relative Strength Index) is hovering just around 56 and could be indicating that a Bigger Breakout is Imminent.
If FDIT RSI crosses over the 60 or 70 Level (Like it has done in the past) there is No-Telling what could happen. We could be witnessing another double, triple or even a quadruple...
We still have another +275% to go until we hit the Goldman Price Target of $.45 (which he already raised once before)
Another big catalyst that could potentially send shares breaking out higher is Wall Streets leading provider of market data Barchart, which upgraded FDIT to a 50% Buy rating short-term, 100% Buy rating medium-term, 100% Buy rating long-term.
Barchart triggered 11 out of 12 Possible Buy Signals across the short-term indicators, medium-term indicators and even the long-term indicators.
I strongly suggest you read the technicals immediately to learn why FDIT has the potential to continue to climb higher!
If you haven't taken a look at this stock yet, this is your chance. Make sure you have FDIT pulled up on your trading screen.
SamuraiStocks
?Trading Research Team